Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN   US09061G1013

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/21/2015 04/22/2015 04/23/2015 04/24/2015 04/27/2015 Date
121.24(c) 121.08(c) 122.95(c) 120.28(c) 120.69 Last
980 304 731 358 1 004 808 821 847 1 023 736 Volume
+0.92% -0.13% +1.54% -2.17% +0.34% Change
More quotes
Financials ($)
Sales 2015 871 M
EBIT 2015 -326 M
Net income 2015 -353 M
Debt 2015 107 M
Yield 2015 -
Sales 2016 1 100 M
EBIT 2016 -147 M
Net income 2016 -212 M
Debt 2016 200 M
Yield 2016 -
PER 2015 -
PER 2016
EV / Sales 2015 22,3x
EV / Sales 2016 17,7x
Capitalization 19 282 M
More Financials
Company
BioMarin Pharmaceutical, Inc. develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions.The company operates its business through one segment, the biopharmaceutical development and commercialization segment.Its company's product portfolio is comprised of... 
Sector
Pharmaceuticals
Calendar
04/30Earnings Release
More about the company
Surperformance© ratings of BioMarin Pharmaceutical In
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOMARIN PHARMACEUTICAL IN
09:43a BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatmen..
04/23 BioMarin Presents Data on Duchenne Muscular Dystrophy at the 67th American Ac..
04/22 BIOMARIN PHARMACEUTICAL : Reports Inducement Grants Under NASDAQ Listing Rule 56..
04/21 BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing R..
04/14 BIOMARIN TO HOST FIRST QUARTER 2015 : 30pm ET
04/14 BIOMARIN PHARMACEUTICAL : to Host First Quarter 2015 Financial Results Conferenc..
04/01DJSarepta Therapeutics CEO Chris Garabedian Resigns -- Update
03/30 BioMarin Announces One Oral and 7 Poster Presentations at the 2015 American C..
More news
Sector news : Generic Pharmaceuticals
11:21a MONDAY SECTOR LAGGARDS : Biotechnology, Drugs
11:20aDJMylan Rejects Teva's Unsolicited $40 Billion Bid -- Update
10:46aDJMylan Rejects Teva's Unsolicited $40 Billion Bid
More sector news : Generic Pharmaceuticals
News from SeekingAlpha
10:24a BioMarin completes rolling NDA submission for drisapersen for DMD
04/24 NEXT WEEK IN BIOTECH : Gilead, Celgene Report; PDUFAs For Theravance, The Medici..
04/23 SANTHERA : the only DMD drug with a successful phase III study
04/22 Capricor cell therapy candidate an Orphan Drug for Duchenne muscular dystroph..
04/16 4 Big Biopharma Deals We Might See In 2015


Comments 
Advertisement
Chart BIOMARIN PHARMACEUTICAL IN
Duration : Period :
BioMarin Pharmaceutical In Technical Analysis Chart | BMRN | US09061G1013 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF